

# High carriage of adherent invasive E. coli in wildlife and healthy individuals

Oumaira Rahmouni, Cecile Vignal, Marie Titecat, Benoit Foligne, Benjamin

Pariente, Laurent Dubuquoy, Pierre Desreumaux, Christel Neut

# ► To cite this version:

Oumaira Rahmouni, Cecile Vignal, Marie Titecat, Benoit Foligne, Benjamin Pariente, et al.. High carriage of adherent invasive E. coli in wildlife and healthy individuals. Gut Pathogens, 2018, Gut Pathogens, 10, pp.23. 10.1186/s13099-018-0248-7. hal-04429524

# HAL Id: hal-04429524 https://hal.univ-lille.fr/hal-04429524v1

Submitted on 31 Jan 2024  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# SHORT REPORT

# **Open Access**



# High carriage of adherent invasive *E. coli* in wildlife and healthy individuals

Oumaïra Rahmouni<sup>1</sup>, Cécile Vignal<sup>1</sup>, Marie Titécat<sup>1,2</sup>, Benoît Foligné<sup>1</sup>, Benjamin Pariente<sup>1,3</sup>, Laurent Dubuquoy<sup>1</sup>, Pierre Desreumaux<sup>1,3</sup> and Christel Neut<sup>1,4\*</sup>

# Abstract

**Background:** Adherent invasive *Escherichia coli* (AIEC) are suspected to be involved in the pathogenesis of inflammatory bowel diseases. Since AIEC was first described in 1999, despite important progress on its genomic and immune characterizations, some crucial questions remain unanswered, such as whether there exists a natural reservoir, or whether there is asymptomatic carriage. The ECOR collection, including *E. coli* strains isolated mainly from the gut of healthy humans and animals, constitutes an ideal tool to investigate AIEC prevalence in healthy condition. A total of 61 *E. coli* strains were examined for characteristics of AIEC.

**Methods:** The adhesion, invasion and intramacrophage replication capabilities (AIEC phenotype) of 61 intestinal *E. coli* strains were determined. The absence of virulence-associated diarrheagenic *E. coli* pathotypes (EPEC, ETEC, EIEC, EHEC, DAEC, EAEC), and uropathogenic *E. coli* was checked.

**Results:** Out of 61 intestinal strains, 13 (21%) exhibit the AIEC phenotype, 7 are from human origin and 6 are from animal origin. Prevalence of AIEC strains is about 24 and 19% in healthy humans and animals respectively. These strains are highly genetically diverse as they are distributed among the main described phylogroups. Among *E. coli* strains from the ECOR collection, we also detected strains able to detach I-407 cells.

**Conclusions:** Our study described for the first time AIEC strains isolated from the feces of healthy humans and animals.

Keywords: Adherent invasive Escherichia coli (AIEC), Healthy individuals, ECOR collection, Pathobiont

## Background

Crohn's disease (CD), one of the clinical presentation of inflammatory bowel diseases (IBD), is characterized by chronic lesions of varying intensity along the gastrointestinal tract resulting from an exacerbated reaction of a defective immune system [1-3]. The etiology of CD is complex and is multifactorial, one of these factors is the state of the intestinal microbiota [4]. Over the last 20 years, *Escherichia coli* has attracted the most attention in respect to CD etiology. A high mucosal colonization level by *E. coli* was first demonstrated in CD [5]. A new pathogenic group of *E. coli*, called adherent invasive *E.* 

\*Correspondence: christelneut@nordnet.fr

<sup>4</sup> Laboratoire de Bactériologie, 3, Rue de Pr. Laguesse, B.P. 83, 59006 Lille Cedex, France

Full list of author information is available at the end of the article



*coli* (AIEC), harboring adhesive and invasive abilities to intestinal epithelial cells, was described [6-8]. The main characteristics of AIEC are (i) the ability to adhere to and invade intestinal epithelial cells, (ii) the ability to survive and replicate expansively within macrophages without triggering host cell death, and (iii) the lack of known invasive determinants [10].

The AIEC strains isolated to date are clonally diverse and belong to distinct serotypes [9–11]. The B2 phylogroup is most prevalent, but strains of A, B1, and D phylogroups have also been isolated [8, 10, 12, 13]. AIEC strains have virulence factors in common with other pathogenic *E. coli* and are closely related to extra-intestinal pathogenic *E. coli* (ExPEC), associated with urinary tract infections and neonatal meningitis [14, 15]. In absence of common and specific genetic signatures between AIEC strains, this pathotype can up to now

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

only be identified by phenotypical traits. AIEC have been described in other human intestinal disorders such as ulcerative colitis (UC), another form of IBD, and colorectal cancer but also in animals with intestinal diseases [16–18]. However, AIEC carriage is not restricted to intestinal inflammatory conditions and AIEC have also been found in biopsies of patients with functional intestinal disorders and in asymptomatic subjects undergoing surveillance colonoscopy, subjects termed as "healthy" in AIEC prevalence studies [6, 9, 12, 13, 16]. A better knowledge of AIEC carriage in healthy condition whether in human or animals will help in understanding more about AIEC natural reservoir and transmission.

The aim of this work was to determine if AIEC is present in the *E. coli* Reference (ECOR) Collection. The ECOR collection is a set of *E. coli* strains of natural origin, isolated from the gastrointestinal tract of healthy humans and non-human mammalians from a variety of geographic locations, and designed to represent the variation and genetic structure of *E. coli* in natural populations [19]. 61 ECOR strains were isolated from feces of healthy hosts (Table 1), making this collection an ideal tool to study the prevalence of AIEC in healthy conditions.

#### Results

# Adherent and invasive capacity of ECOR strains isolated from the feces of healthy individuals

The ECOR collection contains 61 strains of fecal origin. Of these, 29 were from human and 32 from animals (Table 1). An invasion assay was performed on these strains using I-407 cells based on gentamicin protection, according to previously described methods [6, 15, 21, 22]. All of the strains were first tested for their susceptibility to gentamicin using disc diffusion method as only strains susceptible to gentamicin can be tested. All the strains were found to be susceptible to gentamicin, determined as a zone diameter superior to 17 mm, according to EUCAST recommendations.

The invasion levels of the noninvasive references *E. coli* strain K-12 C600 and *E. coli* Nissle were  $0.0561 \pm 0.0373\%$  and  $0.0254 \pm 0.0265\%$  respectively. Reference strain LF82, included in all of the assays as a positive invasive control, gave a mean invasion level of  $1.0101 \pm 0.9880\%$ . Another positive invasive control *E. coli* NRG857c showed a mean invasion of  $0.1683 \pm 0.0368\%$ . The invasion levels were done in triplicate.

Among strains belonging to the ECOR collection, 18 strains (30%) were classified as invasive based on this assay, with invasion rates ranging between 0.10 and 0.64%. Eight of these were of human origin (28%), four belonged to the phylogroup A (ECOR 1, 2, 9 and 15), one to phylogroup B2 (ECOR 63), two to phylogroup D

(ECOR 35 and ECOR 36) and one to the phylogroup E (ECOR 43). Ten were of animal origin (31%), two belonging to the phylogroup A (ECOR 7 and 23), four to the

ing to the phylogroup A (ECOR 7 and 23), four to the phylogroup B1 (ECOR 45, 67, 69 and 70), two to the phylogroup B2 (ECOR 52 and 57) and two to the phylogroup D (ECOR 44 and 46) (Fig. 1).

During the invasion assay, for five of the strains, an unexpected pathogenic feature was discovered: the ability to detach intestinal cells from the microplate. All of these strains were of human origin, one belonging to the phylogroup A (ECOR 6) and the 4 others to the phylogroup B2 (ECOR 51, 53, 54 and 59) (Table 3). Invasion scores of these cell-detaching strains were established but were not interpretable due to their capacity to detach adherent cells from the microplate. The actual concentration of the intracellular bacteria was therefore skewed. Further investigations are necessary to define their propensity to invade.

The strains revealed as invasive were tested for their ability to adhere. All the invasive strains from the ECOR collection were adherent, with an adhesion index ranging between 67 and 334, all showed an adhesion index superior to 1 bacteria per cell (Table 3).

## Virulence genotyping of the invasive strains and cell-detaching strains

The 18 fecal strains previously classified as adherent and invasive were genotyped. The presence of 12 selected virulence genes associated with diarrheagenic *E. coli* pathotype was assessed. This included common virulence factors present in diarrheagenic *E. coli* pathotypes EHEC (*stx-1, stx-2, eae* and *ehxA*), EIEC (*ipaC*), ETEC (*estA, elt* and *tia*), EPEC (*eae, ehxA, bfpA*), EAEC (*aggR* and pCVD432) and DAEC (*afaD*) (Additional file 1: Table S1). Three strains were positive for the *tia* gene (ECOR 57) and *tia* and *afaD* genes (ECOR 63 and 70). These strains are not affiliated as AIEC pathovars and belong to ETEC/ DAEC pathovars. The other 15 invasive strains (ECOR 1, 2, 9, 15, 35, 36, 43, 7, 23, 45, 67, 69, 52, 44, 46) were negative for the tested virulence genes excluding their affiliation to the previously described pathotypes (Table 2).

The cell-detaching strains were also tested for their expression of virulence genes associated of enteropathogenic strains. The ECOR 51 strain was shown to express the *afaD* virulence gene, showing that this strain is classified as a DAEC. The other cell-detaching strains were negative for the tested genes (Table 2).

# Survival and replication ability of the invasive strains from the ECOR collection

The 15 strains revealed as adherent and invasive and without virulence genes associated with diarrheagenic *E. coli* pathotype were tested for their ability to survive and

## Table 1 Fecal strains investigated in this study

ID	Serotype	Phylogroup	Source			ID	Serotype	Phylogroup	Source		
			Host	Sex	Location				Host	Sex	Location
ECOR1	ON:HN	A	Human	Woman	USA	ECOR34	088:NM	B1	Dog		USA
ECOR2	ON:H32	А	Human	Man	USA	ECOR35	O1:NM	D	Human	Man	USA
ECOR3	O1:NM	А	Dog		USA	ECOR36	O79:H25	D	Human	Woman	USA
ECOR4	ON:HN	А	Human	Woman	USA	ECOR37	ON:HN	E	Marmoset		USA
ECOR5	079:NM	А	Human	Woman	USA	ECOR38	O7:NM	D	Human	Woman	USA
ECOR6	ON:NM	А	Human	Man	USA	ECOR39	O7:NM	D	Human	Woman	Sweden
ECOR7	085:HN	А	Orangutan		USA	ECOR41	O7:NM	D	Human	Man	Tonga
ECOR8	086:HN	А	Human	Woman	USA	ECOR42	ON:H26	E	Human	Man	USA
ECOR9	ON:NM	A	Human	Woman	Sweden	ECOR43	ON:HN	E	Human	Woman	Sweden
ECOR10	O6:H10	A	Human	Woman	USA	ECOR44	ON:HN	D	Cougar		USA
ECOR12	07:H32	A	Human	Woman	Sweden	ECOR45	ON:HM	B1	Pig		Indonesia
ECOR13	ON:HN	А	Human	Woman	Sweden	ECOR46	01:H6	D	Celebese ape		USA
ECOR15	O25:NM	А	Human	Woman	Sweden	ECOR47	OM:H18	D	Sheep		New Guinea
ECOR16	ON:H10	А	Leopard		USA	ECOR49	O2:NM	D	Human	Woman	Sweden
ECOR17	0106:NM	А	Pig		Indonesia	ECOR51	025:HN	B2	Human infant		USA
ECOR18	O5:NM	А	Celebese ape		USA	ECOR52	O25:H1	B2	Orangutan		USA
ECOR19	O5:HN	А	Celebese ape		USA	ECOR53	O4:HN	B2	Human	Woman	USA
ECOR20	089:HN	A	Steer		Bali	ECOR54	O25:H1	B2	Human		USA
ECOR21	0121:HN	A	Steer		Bali	ECOR56	O6:H1	B2	Human	Woman	Sweden
ECOR22	ON:HN	A	Steer		Bali	ECOR57	ON:NM	B2	Gorilla		USA
ECOR23	O86:H43	A	Elephant		USA	ECOR58	O112:H8	B1	Lion		USA
ECOR24	015:NM	A	Human	Woman	Sweden	ECOR59	O4:H40	B2	Human	Man	USA
ECOR25	ON:HN	A	Dog		USA	ECOR61	O2:NM	B2	Human	Woman	Sweden
ECOR26	O104:H21	B1	Human infant		USA	ECOR63	ON:NM	B2	Human	Woman	Sweden
ECOR27	0104:NM	B1	Giraffe		USA	ECOR65	ON:H10	B2	Celebese ape		USA
ECOR28	O104:NM	B1	Human	Woman	USA	ECOR66	O4:H40	B2	Celebese ape		USA
ECOR29	O150:H21	B1	Kangaroo rat		USA	ECOR67	O4:H43	B1	Goat		Indonesia
ECOR30	O113:H21	B1	Bison		Canada	ECOR68	ON:NM	B1	Giraffe		USA
ECOR31	O79:H43	E	Leopard		USA	ECOR69	ON:NM	B1	Celebese ape		USA
ECOR32	07:H21	B1	Giraffe		USA	ECOR70	078:NM	B1	Gorilla		USA
ECOR33	07:H21	B1	Sheep		USA						


This table was build according to data from previously published papers [19, 20]

replicate within macrophages. Among these strains, 13 were able to survive and replicate in macrophages. The percent intracellular bacteria at 1 and 24 h postinfection ranged between 114.06 and 881.36%. The ECOR 1, 2, 9, 15, 35, 36, 43, 23, 45, 67, 69, 52, 44 were thus considered as belonging to the AIEC pathotype.

The two other strains (ECOR 46 and 7) were not able to replicate inside macrophages with an index of 70.42 and 74.51% respectively (Table 3). These strains were thus not affiliated to the AIEC pathovar.

# Discussion

The ECOR collection is a collection of *E. coli* that reflects the genetic diversity of non-pathogenic *E. coli* isolated from humans and animals of diverse geographical origins [19] (Table 1). We studied the 61 strains of *E. coli* isolated from the feces of healthy individuals for an invasive phenotype. Our study allowed the demonstration of the presence of AIEC strains in feces of healthy individuals. On the other hand this also gave an insight into the prevalence of AIEC in diverse conditions. Our results showed



that intestinal *E. coli* from the ECOR collection could be divided into three groups according to their phenotypes observed in vitro in I-407 cells: (i) non-invasive strains, (ii) invasive strains defined as AIEC and (iii) strains able to disrupt I-407 cell layer.

Of a total of 61 fecal *E. coli* strains, 48 were not invasive, 18 presented adherent and invasive properties and 5 were able to detach I-407 cells. Out of 18 adherent and invasive strains, 13 were able to survive and replicate inside macrophages, these strains were thus affiliated to the AIEC pathotype. Among all the fecal strains, the prevalence of AIEC was 21% (24% in the human set and 19% among animal strains). All cell-detaching strains were of human origin, which accounted for 8% of the strains among animal and human isolates (17% of all human strains tested). The AIEC pathotype was first described in inflammatory bowel diseases patients. Several independent research groups have reported a higher prevalence of AIEC in biopsies from IBD patients compared to non-IBD controls. However, AIEC prevalence greatly varies between studies. Indeed, AIEC prevalence was shown to range between 10 and 52% in ileal biopsies of CD patients [9–12]. This decreases to 3.7% in colonic biopsies of CD patients, and AIEC has yet to be isolated from colonic biopsies of UC patients [6]. In non-IBD controls, AIEC prevalence was shown to be between 0 and 17% [9–12]. In our study, we showed for the first time that AIEC strains can also be detected in stools of healthy subjects, with a prevalence of 21%.

AIEC pathovars from the ECOR collection are genetically highly diverse as they belong to different phylogroups. Indeed, among the 13 intestinal adherent and

Table 2	Table 2 Characteristics summary of invasive strai	ımary of ir	nvasive stra	ains of fecal origin	rigin												
Origin	Type of strains	٩	Serotype	Phylogroup Source	Source	Virulen	Virulence genes	s									
						stx-1	stx-2	ipaC	estA	elt	tia b	bfpA e	eae e	exhA o	aggR	pCVD432	afaD
Humans	Humans Invasive strains	ECOR1	NH:NO	A	Human, USA	1	1	1	1	1						1	
		ECOR2	ON:H32	A	Human, USA	Ι	I	I	I	I	1	·	1		I	I	I
		ECOR9	ON:NM	A	Human, Sweden	Ι	Ι	Ι	Ι	Ι	1		1		I	Ι	I
		ECOR15	O25:NM	A	Human, Sweden	Ι	Ι	I	Ι	Ι	1	·	1		1	Ι	Ι
		ECOR63	ON:NM	B2	Human, Sweden	Ι	I	I	I	I	+	·	1		I	I	+
		ECOR35	O1:NM	D	Human, USA	Ι	I	Ι	Ι	Ι	1		1		I	Ι	I
		ECOR36	079:H25	Ω	Human, USA	I	I	Ι	Ι	Ι	1	·			I	Ι	I
		ECOR43	NH:NO	Ш	Human, Sweden	Ι	Ι	I	I	Ι	1	·	1		I	Ι	I
Animals		ECOR7	085:HN	A	Orangutan, USA	Ι	I	I	Ι	Ι	1	·	1		I	Ι	I
		ECOR23	086:H43	A	Elephant, USA	Ι	I	Ι	Ι	Ι	1				Ι	Ι	I
		ECOR45	MH:NO	B1	Pig, Indonesia	Ι	Ι	I	I	Ι	1	Ì			I	Ι	Ι
		ECOR67	04:H43	B1	Goat, Indonesia	Ι	I	I	Ι	Ι	1	·	1		I	Ι	I
		ECOR69	MN:NO	B1	Celebese ape, USA	Ι	I	I	I	I	' I	I			I	Ι	I
		ECOR70	078:NM	B1	Gorilla, USA	Ι	Ι	Ι	Ι	Ι	+	I	1		I	Ι	+
		ECOR52	025:H1	B2	Orangutan, USA	Í	Ι	Ι	I	Ι	' I		'		I	I	I
		ECOR57	MN:NO	B2	Gorilla, USA	Ι	Ι	Ι	I	Ι	+		' I	I	I	Ι	Ι
		ECOR44	NH:NO	D	Cougar, USA	Ι	Ι	Ι	Ι	Ι	' I	I			I	Ι	Ι
		ECOR46	01:H6	D	Celebese ape, USA	I	Ι	Ι	Ι	Ι	1		1		I	I	I

origin
f fecal
trains o
vasive s
ofinva
ž
summary o
ary
ary
<b>Characteristics summary</b>

| | | + | |

 $1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1$ 

 $1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1$ 

 $1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1$ 

 $1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1 \quad 1$ 

O25:HN

ECOR51 ECOR53 ECOR54

ECOR6

Humans Cell detaching strains

04:HN 025:H1

01:H6 ON:HM NH:NO

04:H40

ECOR59

Human, USA Human, USA Human, USA Human, USA Human, USA

	ECOR strains	Mean adhesion index	Mean of bacteria recovered at 1 and 24 h postinfection (%)
Invasive strains	ECOR1	197.89±29.77	387.47%±236.00%
	ECOR35	210.53±208.41	881.36%±295.06%
	ECOR52	73.26±2.38	133.33%
	ECOR2	111.58±32.75	168.72%±5.67%
	ECOR36	145.26±68.48	511.41%±70.89%
	ECOR43	82.11±20.84	114.06%±142.24%
	ECOR44	334.74±229.25	255.70%±35.56%
	ECOR45	94.74±20.84	314.08%±268.26%
	ECOR46	92.63±17.86	70.42%
	ECOR7	170.53±74.43	74.51%
	ECOR9	157.89±56.57	152.00%
	ECOR15	153.68±44.66	279.07%
	ECOR23	260.63±48.23	395.48%
	ECOR67	67.37±23.82	361.90%
	ECOR69	117.89±41.68	887.64%
Noninvasive strains	E. coli K12	51.58±16.38	24.59%±2.84
	<i>E. coli</i> Nissle	32.21±8.30	87.78%±131.98%
Invasive strains	AIEC LF82	166.32±20.84	220.59%
	AIEC NRG857c	54.32±4.17	194.90%±39.93

Table 3 Capacity of adhesion in I-407 cells and survival and replication in macrophages among the 15 invasive strains form the ECOR collection

invasive strains identified in this study, 5 belong to the phylogroup A, 3 to the phylogroup B1, 1 to the phylogroup B2, 3 to the phylogroup D and 1 to the phylogroup E. It has been shown that *E. coli* belonging to B2 and D phylogroups possess higher numbers of virulence genes than do A and B1 phylogroups. However, recently, no association was found between the phylogenetic background and the occurrence of diarrhea in calves [23]. The majority of AIEC strains isolated to date, coming from diseased human or animals, belong to the B2 phylogroup [10, 11, 15, 17, 18]. AIEC strains isolated from non-IBD controls (mainly patients suffering from rectorrhagia, hemorrhoids, irritable bowel syndrome, or diverticulitis) also mainly belong to the B2 phylogroup [10]. We showed here that AIEC strains isolated from healthy individuals, either humans or animals, mainly belong to other phylogroups.

Some studies have reported virulence determinant genes and cytotoxic profiles in *E. coli* strains from the ECOR collection [24–27]. Strains revealed to be invasive and capable of detaching I-407 cells were found to express some virulent genes such as pyelonephritis associated pili (*pap*), S-family adhesions (*sfa*), hemolysin (*hly*), long polar fimbriae (*lpf*), and secreted autotransporter toxin (*sat*). Among the 13 adherent and invasive strains, 10 are known to express at least one of these genes (ECOR 2, 35, 36, 43, 23, 45, 67, 69, 52 and 44) and among the five cell-detaching strains, three harbor at least one of these virulence determinants (ECOR 51, 53 and 54) (Table 4). Some of these genes were also found in AIEC strains isolated from biopsies of both IBD and non-IBD patients. Martinez et al. showed that of a total of 16 AIEC strains recovered from biopsies of IBD patients, 8 express *papC* gene, 2 express *sfa*, 4 express *hlya*, and all *fimH*. AIEC strains from non-IBD patients (n=6) also express these genes, 4 were positive for *papC*, 2 for *sfa*, 2 for *hlya* and all for *fimH* [10].

Our work showed for the first time the detection of AIEC strains in healthy animal hosts; one from a healthy orangutan, one from a healthy elephant in captivity, one from a healthy celebese ape in captivity, one from a healthy pig, one from a healthy cougar and one from a healthy goat. These results provide further support for the absence of host specificity of this pathotype [28]. Further studies analyzing the prevalence of AIEC in well-characterized diseased and healthy animals are needed in order to detect putative reservoirs of AIEC strains and to evaluate the dimension of the risk with respect to the implementation of prevention and control measures and to public health.

To conclude, this study showed a prevalence of asymptomatic intestinal carriage of invasive pathogenic *E. coli*,

ollectio
ECOR c
from the
strains
etaching
C and cell-deta
AIEC ar
determinants ir
4 Virulence deter
Table 4

ConstantConstan	ECOR strains			Cell-detaching strains	itrains									References	inces
papel23         + pap123         - + pap123          - + pap123         - + pap123          - + pap123          - + pap123           - + pap123				ECOR53		ECOR51		B	OR6	ECOR	59	ECOR54			
poly 12 to the set of the s	Virulence determinants associ	iated with patho	genicity island	st											
-kgs12+ kgs12- + kgs12- + kgs12+ kgs12+ kgs12+ kgs12-hy2	Two adhesin gene clusters s	fa and pap		+ pap1.2.3 sfa1.2		+ pap1.2.3 sfa1.2		Ι		I		+sfa1.2		Boyd	Boyd et al. [25]
-hy2+hy2-++hy2++-trong haemoysis++NN++-trong haemoysis++NN++-trong haemoysisNNN-++-trong haemoysisNN++-trong haemoysisNN+-trong haemoysisNtrong haemoysistrong haemoysis	The kps capsule operon			+kps1.2		+ kps1.2		I		I		+ kps1.2			
Strong haemolysis     + Strong haemolysis     ND     ND     + Strong haemolysis $C_{1}$ $C_{2}$ $C_{2}$ $C_{2}$ $C_{2}$ $C_{2}$ </td <td>The alpha-hemolysin loci hly</td> <td>/I and hlyll</td> <td></td> <td>+hly2</td> <td></td> <td>+hly2</td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td>+ hly2</td> <td></td> <td></td> <td></td>	The alpha-hemolysin loci hly	/I and hlyll		+hly2		+hly2		I		I		+ hly2			
-frong harmolysis       +frong harmolysis       ND       +frong harmolysis       ND       +frong harmolysis         ND       ND       1       1       1       1       1         ND       1       1       1       1       1       1         ND       1       1       1       1       1       1         ND       1       1       1       1       1       1       1         ND       1	Haemolytic activity														
ND       T       ND       T	PCR detection of the hlyA g	ene		+ Strong haemo	lysis	+ Strong hae	emolysis	NC	0	ND		+ Strong ha	aemolysis	Lai et	Lai et al. [24]
NDNDTNDTTT11 </td <td>Distribution of STEC-IpfAs</td> <td></td>	Distribution of STEC-IpfAs														
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Four IpfA genetic variants de IpfA0157/0I-154, IpfA026	signated IpfAO1 and IpfAO113	157/0I-141,	I		QN		I		I		I		Toma	Toma et al. [26]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Antibiotic resistance in the EC	OR collection													
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Streptomycin			I		I		I		Ι		I		Mazel	Mazel et al. [32]
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Spectinomycin			I		I		I		I		I			
-       -       +       +       -	Sulfonamide			I		I		I		Ι		+			
- $   -$	Tetracyclin			I		I		+		I		I			
Consist<	Ampicillin			I		Ι		I		Ι		Ι			
-       -	Kanamycin			I		I		I		I		I			
-       -	Chloramphenicol			I		I		I		I		I			
<b>FCOR36ECOR69ECOR32ECOR1ECOR35ECOR45ECOR45</b> + pap12.3-+ pap12.3-+ pap12.3-+ pap1+ kps12-+ kps12.3-+ pap12.3+ kps12-+ kps12.3+ pap12.3+ kps12-+ kps12.3+ kps12+ kps12+ kps12+ kps12+ kps12.3+ kps12+ kps12+ kps12+ kps12NDNDNDNDNDNDND+ 5tongNDNDNDIpfAO113+IpfAO113+IpfAO113+IpfAO113+NDNDNDNDND <td>Mercuric chloride</td> <td></td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td></td> <td></td>	Mercuric chloride			I		I		I		I		I			
ECOR36ECOR59ECOR52ECOR1ECOR3ECOR35ECOR45ECOR45+ pap12.3-+ pap12.3-+ pap12.3-+ pap1-+ kps12-+ kps12.3-+ pap12.3-+ pap1+ kps12.3+ pap12.3+ kps12.3+ kps12.3NDNDNDNDNDNDNDhpfA0113+hpfA0113+hpfA0113+hpfA0113+hpfA0113+hpfA0113+ <td>Ethidium bromide</td> <td></td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td>I</td> <td></td> <td></td> <td></td>	Ethidium bromide			I		I		I		I		I			
ECOR36ECOR69ECOR32ECOR1ECOR3ECOR35ECOR45 $+ pap123$ $ + pap123$ $ + pap123$ $ + pap123$ $ + kps12$ $ + kps12$ $ + kps12$ $  + kps12$ $   + kps12$ $         + kps12$ $         + kps12$ $         + kps12$ $         + kps12$ $         + kps12$ $   -$	ECOR strains	AIEC phenoty	pe												References
+ pap1.2.3       -       + pap1.2.3       -       + pap1.2.3       -       + pap1       -         + kps1.2       -       + kps1.2       -       -       + kps1.2       -       -         -       -       + kps1.2       -       -       -       -       -       -       -         -       -       + kps1.2       - <td></td> <td>ECOR43</td> <td>ECOR23</td> <td>ECOR36</td> <td>ECOR69</td> <td>ECOR52</td> <td>ECOR1</td> <td>ECOR2</td> <td></td> <td></td> <td>COR35</td> <td>ECOR45</td> <td>ECOR67</td> <td>ECOR44</td> <td></td>		ECOR43	ECOR23	ECOR36	ECOR69	ECOR52	ECOR1	ECOR2			COR35	ECOR45	ECOR67	ECOR44	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Virulence determinants associ	iated with patho	genicity island	ds											
i +hy2 - +kps1.2 - +kps1.2 - +kps1.2 - +kps1.2 +kps1.2 - +kps1.2 - +hy2 +hy2 +hy2 +kps1.2 +hy2 +hy2 +hy2	Two adhesin gene clusters sfa and pap	I	I	+ pap1.2.3	I	+ pap1.2.3 sfa1.2	I	+ pap1.2.3			- pap1	I	I	+ pap1.2.3	Boyd et al. [25]
i         +hy2         -         -         +hy2         - </td <td>The kps capsule operon</td> <td>I</td> <td>I</td> <td>+ kps1.2</td> <td>I</td> <td>+ kps1.2</td> <td>I</td> <td>I</td> <td></td> <td></td> <td>- kps1.2</td> <td>Ι</td> <td>I</td> <td>+ kps1.2</td> <td></td>	The kps capsule operon	I	I	+ kps1.2	I	+ kps1.2	I	I			- kps1.2	Ι	I	+ kps1.2	
A No haemoly- ND ND ND + Strong ND ND ND ND ND ND sis s  pfAO26+  pfAO113+  pfAO113+  pfAO113+  pfAO113+  pfAO26+  pfAO113+  pfAO113+  pfAO113+  pfAO26+  pfAO113+  pfAO113+  pfAO113+	The alpha-hemolysin loci hlyl and hlyll	+ hly2	I	I	I	+ hly2	I	I				I	I	I	
A         No haemoly-         ND	Haemolytic activity														
s lpfAO26+ lpfAO26+ lpfAO113+ lpfAO113+ lpfAO113+ lpfAO26+ lpfAO157/ lpfAO113+ 54, OI-141+	PCR detection of the hlyA gene	No haemoly- sis	QN	ND	QN	+ Strong haemolysis	Q	QN			Q	QN	QN	QN	Lai et al. [24]
pfA026+  pfA026+  pfA0113+  pfA0113+  pfA0113+  pfA026+  pfA0157/  pfA0113+ 4, 01-141+	Distribution of STEC-IpfAs														
	Four lpfA genetic variants designated lpfAO157/ OI-141, lpfAO157/OI-154, lpfAO26 and lpfAO113	lpfAO26+ lpfAO157/ OI-141+	lpfAO26+ lpfAO113+	lpfA0113+	lpfA0113+	I	I	I				lpfAO26+ lpfAO113+	lpfAO26+ lpfAO113+	lpfA0113+	Toma et al. [26]

σ
CD
ž
⊒.
•=
-
<u> </u>
-
0
U U
-
4
•
e e
_
0
ap
6

ECOR strains	AIEC phenotype	ype												References
	ECOR43	ECOR43 ECOR23 ECOR3	ECOR36	ECOR69	ECOR52	ECOR1	ECOR2	ECOR9	ECOR15	ECOR35	ECOR1 ECOR2 ECOR9 ECOR15 ECOR35 ECOR45	ECOR67	ECOR44	
ce in the l	COR collection													
Streptomycin	I	I	I	I	I	I	I			I	I	I	I	Mazel et al.
Spectinomycin	Ι	Ι	I	Ι	Ι	Ι	I			I	I	Ι	I	[32]
Sulfonamide	I	Ι	I	I	I	Ι	I			I	I	I	I	
Tetracyclin	I	Ι	I	I	Ι	I	I			I	I	I	I	
Ampicillin	Ι	Ι	I	Ι	Ι	Ι	I			I	I	Ι	Ι	
Kanamycin	I	Ι	Ι	I	Ι	I	Ι	I	I	I	I	I	I	
Chloramphenicol	I	Ι	Ι	I	Ι	I	I	I	I	I	I	I	I	
Mercuric chloride	I	Ι	I	I	Ι	I	I			I	I	I	I	
Ethidium bromide	I	I	I	I	Ι	I	I		I	I	Ι	I	I	

supporting the argument that AIEC may be considered as pathobiont [9, 16, 29]. Large-scale studies in humans (both CD and UC patients, irritable bowel disease patients and healthy individuals) are necessary for a better knowledge of AIEC distribution and are currently in progress in our laboratory. Our clinical study is consistent with these data, showing notably a high prevalence of AIEC in feces of healthy individuals (manuscript in preparation).

## Conclusions

Our study has evaluated the prevalence of AIEC in the standard reference *E. coli* collection (ECOR). Among all the strains from the ECOR collection, 21% exhibited the AIEC phenotype, 24% were from healthy human origin and 19% from different healthy animal hosts. This is of major interest from an epidemiological point of view, highlighting potential environmental niches and possible human transmission of AIEC and susceptibility in further inflammatory events in a healthy population.

## Methods

#### **Bacterial strains**

Bacteria from the ECOR collection were kindly provided by Laurent Debarbieux (Institut Pasteur Paris) (Table 1). *E. coli* referent strains belonging to different pathogenic groups respectively ETEC (ATCC 35401), EHEC (ATCC 43895), EPEC (ATCC 43887), EAEC (ATCC 33780), EIEC (ATCC 43893), DAEC (AfaA30, kindly provided by Pr Eric Oswald, IRSD, INSERM UMR 1220, Toulouse, France) were used as positive controls in PCR genotyping; while *E. coli* K12 was used as a negative control. *E. coli* ATCC 25922 was used as a positive control for the gentamicin susceptibility assay. Bacteria were routinely grown on Luria–Bertani (LB) agar plates or in LB broth at 37 °C.

#### Gentamicin susceptibility assay

All the strains were assessed for their susceptibility to gentamicin by applying the in vitro diffusion method. Agar plates were inoculated with a 0.5 McFarland bacterial suspension. Then, gentamicin discs (Oxoid, 10  $\mu$ g) were placed in the inoculated media and incubated at 37 °C for 24 h. The susceptibility of the bacteria to gentamicin was determined by measurement of the diameters of the inhibition zones surrounding the discs in millimeters according EUCAST values. A control standard strain (*E. coli* ATCC 25922) for which the susceptibility to antimicrobial agents is known is included in the test to validate the assay [30].

#### Cells

Intestine-407 cell lines (I-407, ATCC accession number CCL-6<sup>TM</sup>) were used to determine bacterial invasiveness. I-407 cells were maintained in Basal medium Eagle (BME, Thermofisher, France) with 10% heat-inactivated fetal calf serum (Euroclone Italy) supplemented with 1% Glutamax and 1% penicillin/streptomycin (Thermofisher, France), in 5% CO<sub>2</sub> atmosphere at 37 °C.

## Adhesion and invasion assays in epithelial cells Intestine-407

For AIEC identification, adhesion and invasion assays, based on gentamicin protection, were performed according to a previously described method [6, 15, 21, 22]. 24-well plates containing  $4 \times 10^5$  cells/well incubated for 20 h without antibiotics were infected with the E. coli strains at a multiplicity of infection of 10 during 3 h of incubation time. For the bacterial adhesion assays, the cell monolayers were washed with phosphate-buffered saline and then lysed with 1% Triton X-100. Adherent bacteria were quantified by plating them on LB agar. Plating was performed over a maximum period of 30 min in order to avoid bacterial lysis by Triton X-100. Adherence ability (I\_ADH) was determined by calculating the mean number of bacteria per cell. For the bacterial invasion assays, cells were washed twice with phosphate buffer saline (PBS), and fresh cell culture medium containing 100  $\mu$ g ml<sup>-1</sup> of gentamicin was added for 1 h to kill extracellular bacteria. Cells were then washed three times with PBS and 1 ml of 1% Triton X-100 was added in each well for 5 min to lyse the eukaryotic cells. After cell lysis, the number of intracellular bacteria was determined by plating. The invasive ability was expressed as the percentage of intracellular E. coli recovered from the initial inoculum, taken as 100%. An isolate was considered invasive when invasion was  $\geq$  0.1%. Each experiment was done in triplicate. The non-invasive strains of E. coli K12 and E. coli Nissle and the invasive AIEC LF82 and AIEC NRG857c strains were used as negative and positive control in each experiment.

#### Survival and replication in J774 macrophages

The macrophage-like J774A.1 cell line (ATCC TIB-67) was used as a model in *E. coli* survival and replication assays. *E. coli* isolates with known adherence and invasion properties were checked for their ability to survive and replicate inside macrophages. Briefly, macrophages were seeded at  $4 \times 10^5$  cells per well in two 24-well plates and incubated for 20 h. After incubation, the medium was replaced with fresh medium and bacteria were

seeded at a multiplicity of infection of 100. To promote internalization of bacteria by the macrophages, the samples were centrifuged at 1000 rpm for 10 min and incubated for an additional 10 min at 37 °C with 5% CO<sub>2</sub>. Nonphagocytosed bacteria were killed with gentamicin. Intracellular bacteria were quantified in the same manner as described for the invasion assays after 1 and 24 h of infection. The results are expressed as the mean percentages of bacteria recovered at 1 and 24 h postinfection: I\_REPL (%) = (CFU ml<sup>-1</sup> at 24 h/CFU ml<sup>-1</sup> at 1 h) × 100. Those strains with an I\_INV of >0.1 and an I\_REPL of >100% were classified as AIEC strains in the present study. All assays were performed in duplicate.

#### Virulence genotyping by polymerase chain reaction (PCR)

DNA was extracted from bacteria by suspending one bacterial colony in 50  $\mu$ l of deionized water, boiling the suspension for 10 min, and centrifuging it at  $10,000 \times g$  for 1 min. The supernatant was then used as the DNA template for PCR.

The presence of 12 virulence genes specifically associated with diarrheagenic *E. coli* pathotypes (EPEC, ETEC, EIEC, EHEC, DAEC, EAEC), and uropathogenic *E. coli* (UPEC) was analyzed (Additional file 1: Table S1) [8, 31]. *E. coli* reference strains were used as positive controls.

Adherent/invasive bacteria able to survive and to multiply within macrophage, without expressing virulence genes associated with diarrheagenic *E. coli* pathotypes and uropathogenic *E. coli* were considered as AIEC strains.

## **Additional file**

Additional file 1: Table S1. Primers used for *E. coli* virulence genes detection.

#### Abbreviations

AIEC: adherent invasive *Escherichia coli*; BME: Basal medium eagle; CD: Crohn's disease; ECOR: *Escherichia coli* Reference Collection; FCS: Fetal calf serum; I-407: Intestine-407 cell lines; IBD: inflammatory bowel disease; IEC: intestinal epi-thelial cells; LB: Luria Bertani; MLEE: multilocus enzyme electrophoresis; PBS: phosphate buffer saline; PCR: polymerase chain reaction; S: susceptible; TNF: tumor necrosis factor; UC: ulcerative colitis; USA: United States of America.

#### Authors' contributions

OR, MT and CV designed, performed and analyzed experiments. PD and LD conceived and designed the project. OR, MT, CN interpreted data. OR and CN wrote the manuscript. PD, LD, CN and BP supervised the study. BF, CN and CV critically revised the manuscript. PD and CN obtained funding. All authors read and approved the final manuscript.

#### Author details

<sup>1</sup> Lille Inflammation Research International Center, UMR 995 Inserm, Lille University, CHRU Lille, Lille, France. <sup>2</sup> Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France. <sup>3</sup> Service des Maladies de l'Appareil Digestif et de la Nutrition, Hôpital Claude Huriez, CHU Lille, 59037 Lille, France. <sup>4</sup> Laboratoire de Bactériologie, 3, Rue de Pr. Laguesse, B.P. 83, 59006 Lille Cedex, France.

#### Acknowledgements

We are grateful to Dr. Laurent Debarbieux (Institut Pasteur Paris) for the gift of the ECOR collection strains. We also thank Pr Eric Oswald for the *E. coli* referent strains belonging to different pathogenic groups.

#### Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

#### · · · F.F. · · · · ·

**Consent for publication** 

Not applicable.

Not applicable

#### Ethics approval and consent to participate

Not applicable.

#### Funding

We would like to thank DigestScience foundation for their financial support.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 16 March 2018 Accepted: 23 May 2018 Published online: 14 June 2018

#### References

- 1. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313–21.
- de Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
- 3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–34.
- Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152:327–39.
- Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54.
- Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser A-L, Barnich N, Bringer M-A, Swidsinski A, Beaugerie L, Colombel J-F. High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004;127:412–21.
- Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, Barnich N, Ng SC, Colombel J-F. Adherent-invasive *Escherichia coli* in inflammatory bowel disease. Gut. 2017;67:574–87.
- Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced *Escherichia coli* adherence and invasion in Crohn's disease and colon cancer. Gastroenterology. 2004;127:80–93.
- Conte M, Longhi C, Marazzato M, Conte A, Aleandri M, Lepanto M, Zagaglia C, Nicoletti M, Aloi M, Totino V, Palamara A, Schippa S. Adherentinvasive *Escherichia coli* (AIEC) in pediatric Crohn's disease patients: phenotypic and genetic pathogenic features. BMC Res Notes. 2014;7:748.
- Martinez-Medina M, Aldeguer X, Lopez-Siles M, González-Huix F, López-Oliu C, Dahbi G, Blanco JE, Blanco J, Garcia-Gil LJ, Darfeuille-Michaud A. Molecular diversity of *Escherichia coli* in the human gut: new ecological evidence supporting the role of adherent-invasive *E. coli* (AIEC) in Crohn's disease. Inflamm Bowel Dis. 2009;15:872–82.
- Céspedes S, Saitz W, Del Canto F, De la Fuente M, Quera R, Hermoso M, Muñoz R, Ginard D, Khorrami S, Girón J, Assar R, Rosselló-Mora R, Vidal RM. Genetic diversity and virulence determinants of *Escherichia coli* strains isolated from patients with Crohn's disease in Spain and Chile. Front Microbiol. 2017;8:639.
- Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW. Culture independent analysis of ileal mucosa reveals a

selective increase in invasive *Escherichia coli* of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 2007;1:403–18.

- Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JMA. Invasive *Escherichia coli* are a feature of Crohn's disease. Lab Invest. 2007;87:1042–54.
- Nash JH, Villegas A, Kropinski AM, Aguilar-Valenzuela R, Konczy P, Mascarenhas M, Ziebell K, Torres AG, Karmali MA, Coombes BK. Genome sequence of adherent-invasive *Escherichia coli* and comparative genomic analysis with other *E. coli* pathotypes. BMC Genomics. 2010;11:667.
- Martinez-Medina M, Mora A, Blanco M, López C, Alonso MP, Bonacorsi S, Nicolas-Chanoine M-H, Darfeuille-Michaud A, Garcia-Gil J, Blanco J. Similarity and divergence among adherent-invasive *Escherichia coli* and extraintestinal pathogenic *E. coli* strains. J Clin Microbiol. 2009;47:3968–79.
- Martinez-Medina M, Garcia-Gil LJ. *Escherichia coli* in chronic inflammatory bowel diseases: an update on adherent invasive *Escherichia coli* pathogenicity. World J Gastrointest Pathophysiol. 2014;3:213–27.
- Simpson KW, Dogan B, Rishniw M, Goldstein RE, Klaessig S, McDonough PL, German AJ, Yates RM, Russell DG, Johnson SE, Berg DE, Harel J, Bruant G, McDonough SP, Schukken YH. Adherent and invasive *Escherichia coli* is associated with granulomatous colitis in boxer dogs. Infect Immun. 2006;74:4778–92.
- Martinez-Medina M, Garcia-Gil J, Barnich N, Wieler LH, Ewers C. Adherentinvasive *Escherichia coli* phenotype displayed by intestinal pathogenic *E. coli* strains from cats, dogs, and swine. Appl Environ Microbiol. 2011;77:5813–7.
- 19. Ochman H, Selander RK. Standard reference strains of *Escherichia coli* from natural populations. J Bacteriol. 1984;157:690–3.
- Clermont O, Cordevant C, Bonacorsi S, Marecat A, Lange M, Bingen E. Automated ribotyping provides rapid phylogenetic subgroup affiliation of clinical extraintestinal pathogenic *Escherichia coli* strains. J Clin Microbiol. 2001;39:4549–53.
- Drouet M, Vignal C, Singer E, Djouina M, Dubreuil L, Cortot A, Desreumaux P, Neut C. AIEC colonization and pathogenicity: influence of previous antibiotic treatment and preexisting inflammation. Inflamm Bowel Dis. 2012;18:1923–31.
- 22. Boudeau J, Glasser AL, Masseret E, Joly B, Darfeuille-Michaud A. Invasive ability of an *Escherichia coli* strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun. 1999;67:4499–509.

- Coura FM, de Araújo Diniz S, Mussi JMS, Silva MX, Lage AP, Heinemann MB. Characterization of virulence factors and phylogenetic group determination of *Escherichia coli* isolated from diarrheic and non-diarrheic calves from Brazil. Folia Microbiol. 2017;62:139–44.
- Lai XH, Wang SY, Uhlin BE. Expression of cytotoxicity by potential pathogens in the standard *Escherichia coli* collection of reference (ECOR) strains. Microbiology. 1999;145:3295–303.
- Boyd EF, Hartl DL. Chromosomal regions specific to pathogenic isolates of *Escherichia coli* have a phylogenetically clustered distribution. J Bacteriol. 1998;180:1159–65.
- Toma C, Higa N, Iyoda S, Rivas M, Iwanaga M. The long polar fimbriae genes identified in Shiga toxin-producing *Escherichia coli* are present in other diarrheagenic *E. coli* and in the standard *E. coli* collection of reference (ECOR) strains. Res Microbiol. 2006;157:153–61.
- Restieri C, Garriss G, Locas M-C, Dozois CM. Autotransporter-encoding sequences are phylogenetically distributed among *Escherichia coli* clinical isolates and reference strains. Appl Environ Microbiol. 2007;73:1553–62.
- Dogan B, Suzuki H, Herlekar D, Sartor RB, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP, Lefébure T, Chandler B, Schukken YH, Stanhope MJ, Simpson KW. Inflammation-associated adherent-invasive *Escherichia coli* are enriched in pathways for use of propanediol and iron and M-cell translocation. Inflamm Bowel Dis. 2014;20:1919–32.
- 29. Chassaing B, Koren O, Carvalho FA, Ley RE, Gewirtz AT. AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut. 2014;63:1069–80.
- European Committee on Antimicrobial Susceptibility Testing. http:// www.eucast.org/clinical\_breakpoints/.
- Cabal A, Gómez-Barrero S, Porrero C, Bárcena C, López G, Cantón R, Gortázar C, Domínguez L, Álvarez J. Assessment of virulence factors characteristic of human *Escherichia coli* pathotypes and antimicrobial resistance in O157:H7 and non-O157:H7 isolates from livestock in Spain. Appl Environ Microbiol. 2013;79:4170–2.
- Mazel D, Dychinco B, Webb V-A, Davies J. Antibiotic resistance in the ECOR collection: integrons and identification of a novel aad gene. Antimicrob. Agents Chemother. 2000;44:1568–74

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

